IN2012DN03361A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN03361A IN2012DN03361A IN3361DEN2012A IN2012DN03361A IN 2012DN03361 A IN2012DN03361 A IN 2012DN03361A IN 3361DEN2012 A IN3361DEN2012 A IN 3361DEN2012A IN 2012DN03361 A IN2012DN03361 A IN 2012DN03361A
- Authority
- IN
- India
- Prior art keywords
- microparticles
- disclosed
- treating
- macular
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5089—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24784809P | 2009-10-01 | 2009-10-01 | |
US24784909P | 2009-10-01 | 2009-10-01 | |
PCT/US2010/051068 WO2011041642A1 (en) | 2009-10-01 | 2010-10-01 | Microparticle compositions and methods for treating age-related macular degeneration |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2012DN03361A true IN2012DN03361A (no) | 2015-10-23 |
Family
ID=43085447
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN3361DEN2012 IN2012DN03361A (no) | 2009-10-01 | 2010-10-01 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20110104151A1 (no) |
EP (1) | EP2482804A1 (no) |
JP (1) | JP2013506693A (no) |
KR (1) | KR20120095371A (no) |
CA (1) | CA2776472A1 (no) |
IN (1) | IN2012DN03361A (no) |
WO (1) | WO2011041642A1 (no) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG194471A1 (en) * | 2011-05-27 | 2013-12-30 | Novartis Ag | Method of treating vision disorders |
WO2013075068A1 (en) * | 2011-11-18 | 2013-05-23 | Regeneron Pharmaceuticals, Inc. | Polymer protein microparticles |
AU2013212583A1 (en) * | 2012-01-23 | 2014-08-14 | Allergan, Inc. | Time released biodegradable or bioerodible microspheres or microparticles suspended in a solidifying depot-forming injectable drug formulation |
KR20200065106A (ko) | 2012-09-27 | 2020-06-08 | 알레간 인코포레이티드 | 단백질의 지속된 방출을 위한 생물분해성 약물 전달 시스템 |
RU2720412C2 (ru) | 2013-03-14 | 2020-04-29 | Аллерган, Инк. | Композиции доставки с замедленным высвобождением и способ стабилизации белков в процессе изготовления |
KR102016421B1 (ko) | 2016-10-28 | 2019-08-30 | 부산대학교 산학협력단 | 치자 추출물로 표면 처리된 금 나노입자를 유효성분으로 함유하는 황반변성 예방 또는 치료용 조성물 |
KR20200029374A (ko) * | 2018-09-10 | 2020-03-18 | 삼성바이오에피스 주식회사 | 단백질을 포함하는 액상 조성물 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) * | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
ES2084698T5 (es) | 1989-05-04 | 2005-03-01 | Southern Research Institute | Procedimiento de encapsulacion. |
US20060172972A1 (en) * | 2002-12-20 | 2006-08-03 | Chakshu Research Inc | Formulation and method for administration of ophthalmologically active agents |
US20050255144A1 (en) * | 2003-04-09 | 2005-11-17 | Directcontact Llc | Methods and articles for the delivery of medicaments to the eye for the treatment of posterior segment diseases |
WO2005110374A1 (en) * | 2004-04-30 | 2005-11-24 | Allergan, Inc. | Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component |
US20060182783A1 (en) * | 2004-04-30 | 2006-08-17 | Allergan, Inc. | Sustained release intraocular drug delivery systems |
US20070059336A1 (en) * | 2004-04-30 | 2007-03-15 | Allergan, Inc. | Anti-angiogenic sustained release intraocular implants and related methods |
CA2584305A1 (en) * | 2004-10-21 | 2006-05-04 | Genentech, Inc. | Method for treating intraocular neovascular diseases |
US20060246146A1 (en) * | 2005-04-29 | 2006-11-02 | Mcmahon Robert J | Method of increasing the salivary sialic acid content in a mammal |
WO2007131050A2 (en) * | 2006-05-02 | 2007-11-15 | Georgia Tech Research Corporation | Method for drug delivery to ocular tissue using microneedle |
EP2037977A2 (en) * | 2006-06-28 | 2009-03-25 | SurModics, Inc. | Active agent eluting matrices with particulates |
US8039010B2 (en) * | 2006-11-03 | 2011-10-18 | Allergan, Inc. | Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier |
US8231892B2 (en) * | 2007-05-24 | 2012-07-31 | Allergan, Inc. | Biodegradable drug delivery system |
US8821870B2 (en) * | 2008-07-18 | 2014-09-02 | Allergan, Inc. | Method for treating atrophic age related macular degeneration |
US20100189800A1 (en) * | 2009-01-23 | 2010-07-29 | Peter Markland | Continous double emulsion process for making microparticles |
-
2010
- 2010-10-01 EP EP10762843A patent/EP2482804A1/en not_active Withdrawn
- 2010-10-01 US US12/896,278 patent/US20110104151A1/en not_active Abandoned
- 2010-10-01 CA CA2776472A patent/CA2776472A1/en not_active Abandoned
- 2010-10-01 WO PCT/US2010/051068 patent/WO2011041642A1/en active Application Filing
- 2010-10-01 KR KR1020127011153A patent/KR20120095371A/ko not_active Application Discontinuation
- 2010-10-01 IN IN3361DEN2012 patent/IN2012DN03361A/en unknown
- 2010-10-01 JP JP2012532347A patent/JP2013506693A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2011041642A1 (en) | 2011-04-07 |
KR20120095371A (ko) | 2012-08-28 |
CA2776472A1 (en) | 2011-04-07 |
US20110104151A1 (en) | 2011-05-05 |
EP2482804A1 (en) | 2012-08-08 |
JP2013506693A (ja) | 2013-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12020550450A1 (en) | Certain chemical entities, compositions and methods | |
PH12019502269A1 (en) | Quinazoline derivatives for the treatment of viral infections and further diseases | |
MX2020009780A (es) | Compuestos de inhibidor de autotaxina. | |
IN2012DN02469A (no) | ||
TN2013000348A1 (en) | Compounds and compositions as trk inhibitors | |
IN2012DN03361A (no) | ||
GB201209613D0 (en) | New compounds | |
MX2012004078A (es) | Compuestos y composiciones como moduladores de la actividad de gpr119. | |
EA024842B9 (ru) | Соединения в качестве модуляторов протеинкиназы pi3k | |
PH12014501967A1 (en) | Benzodioxanes in combination with other actives for inhibiting leukotriene production | |
SG10201903119QA (en) | Polypeptide vaccine | |
MX2015012435A (es) | Derivados de 3-fenilpropilamina sustituidos para el tratamiento de enfermedades y trastornos oftalmicos. | |
TN2011000647A1 (en) | Fused imidazoles and compositions comprising them for the treatment of parasitic diseases such as e.g. malaria | |
MX2015007916A (es) | Peri-carbinoles. | |
MX336711B (es) | Inhibidores de catecol o-metil transferasa y su uso en el tratamiento de transtornos psicoticos. | |
MX337849B (es) | Composiciones y metodos para inhibicion de la via jak. | |
TN2014000131A1 (en) | Estra-1,3,5(10),16-tetraene-3-carboxamide derivatives, process for preparation thereof, pharmaceutical preparations comprising them, and use thereof for production of medicaments | |
MX2013000958A (es) | Fabricación del inhibidor-inter-alfa (iaip) a partir de plasma. | |
MX2012006430A (es) | Preparaciones de combinacion que comprenden un antagonista de citocina y un corticosteroide. | |
IN2015KN00492A (no) | ||
WO2011127048A3 (en) | NON-HORMONAL STEROID MODULATORS OF NF-ĸB FOR TREATMENT OF DISEASE | |
GB201213484D0 (en) | Pharmaceutical compositions comprising 15-OHEPA and methods of using the same | |
MX2013015347A (es) | Terapia direccionada al receptor del factor de crecimiento epidermico (egfr). | |
WO2011014520A3 (en) | Compounds and compositions as modulators of gpr119 activity | |
MX2018009662A (es) | Metodo y composicion farmaceutica para tratamiento de neurodegeneracion. |